MRSA Colonization
Conditions
Keywords
MRSA decolonization, MRSA subtyping, MRSA infection rates
Brief summary
All trauma patients admitted to certain Intensive Care Units (ICU) will have Methicillin-resistant Staphylococcus aureus (MRSA) nasal swabs performed to determine MRSA colonization status. Only those patients who are determined to be colonized with MRSA at admission will be included in the study. All patients must be age 18 and older, admitted directly to the ICU from either the Emergency Department or the operating room with trauma-related injuries, and must not have active or recent known history of MRSA infections. Once patients have been determined to be colonized with MRSA, they will be randomized to receive decolonization treatment or placebo. Decolonization treatment will include Chlorhexidine baths and Mupirocin ointment to both nares for 5 days and placebo will entail routine soap baths and Lubricating Jelly. Both groups will be kept on standard contact precautions throughout the course of the study. Repeat nasal swabs will be performed at the completion of the treatment regimen to determine the efficacy. Patients will be screened for invasive MRSA infections as dictated by their clinical course. The primary outcome measure will be invasive MRSA infection rate (pneumonia, urinary tract infection, bacteremia and soft tissue infection). Secondary endpoints include hospital lengths of stay, ICU lengths of stay, mechanical ventilatory support requirements, colonization status at the end of treatment, and death rates. As determined by our power analysis, we aim to enroll 75 patients in each arm over the course of 12-24 months.
Detailed description
Partway through the enrollment period, it was determined that in the best interests of the patients, the protocol would be altered to eliminate the randomization process and treat all patients with the decolonization treatment regimen.
Interventions
DRUGSoap baths, Lubricating Jelly
Soap and water baths with lubricating jelly to the nares, once daily for 5 days
DRUGChlorhexidine, Mupirocin
Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
Sponsors
United States Department of Defense
University of Tennessee
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* colonized with MRSA at admission * age of 18 years or older * admitted directly to the ICU from either the ED or the OR with trauma-related injuries
Exclusion criteria
* active or recent known history of MRSA infection * previous institutionalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients decolonized following treatment | Up to 24 months | Measurement of decolonization of MRSA as determined by polymerase chain reaction (PCR) from the nares of critically ill trauma population following treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of decolonized patients who develop further infections versus number of infections developed by patients who remain colonized | up to 24 months | Evaluate the difference between the number of patients who are decolonized following treatment who later develop invasive MRSA infections versus those who remain colonized and develop infections. |
| Evaluate the genotype and virulence factors of initial colonization and additional MRSA sources | up to 24 months | Evaluate the genotypes of the initial MRSA sampled and additional sources developed by the patient. This will determine if patients are developing additional infections from outside sources or from the same strain of MRSA with which they were originally colonized. |
Countries
United States
Outcome results
None listed